Showing 1,501 - 1,520 results of 43,662 for search '(( 5 ((nn decrease) OR (mean decrease)) ) OR ( a ((point decrease) OR (fold decrease)) ))', query time: 0.96s Refine Results
  1. 1501
  2. 1502
  3. 1503
  4. 1504
  5. 1505
  6. 1506

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  7. 1507

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  8. 1508

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  9. 1509

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  10. 1510

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  11. 1511

    Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression. by Megan Stevens (3964886)

    Published 2019
    “…<b>C)</b> Under both NG and HG condition, delphinidin significantly decreased the protein expression of total VEGF-A<sub>165</sub> (*p<0.05; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs). …”
  12. 1512

    TGFβ1 expression was increased, and RASAL1 expression was decreased in NTM cells in response to a hypoxic environment. by Fiona McDonnell (2636635)

    Published 2016
    “…</b> After 24 hours, RASAL1 was decreased; fold change 0.51+/-0.13 (P<0.05). <b>C.</b> Western blotting shows an apparent increase in TGFβ1 after 6 hours. …”
  13. 1513

    Heatmap of fold-changes of metabolites. by Elena Heidenreich (6940475)

    Published 2019
    “…A) Metabolite fold-change per cell, B) Metabolite fold-change per POC.…”
  14. 1514
  15. 1515
  16. 1516
  17. 1517
  18. 1518
  19. 1519

    Decreased Brain Levels of Vitamin B12 in Aging, Autism and Schizophrenia by Yiting Zhang (391974)

    Published 2016
    “…Total Cbl was significantly lower in older control subjects (> 60 yrs of age), primarily reflecting a >10-fold age-dependent decline in the level of MeCbl. …”
  20. 1520